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Abstract 
Calcium pyrophosphate dihydrate (CPPD) and basic calcium phosphate (BCP) crystal deposition diseases are a group of heteroge- 
neous arthritides which are a significant source of morbidity in the elderly. Both crystals induced mitogenesis and metalloproteinase (MP) 
synthesis and secretion by fibroblasts and chondrocytes which may promote degradation of intra-articular tissue. We have previously 
shown that phosphocitrate (PC), an inhibitor of hydroxyapatite crystallization, specifically blocks BCP crystal-induced mitogenesis in 3T3 
cells. This led us to examine the effect of PC on BCP and CPPD crystal induction of MP synthesis in human fibroblasts. PC (10 -3 to 
10 -4 M) specifically inhibited the crystal-induced collagenase and stromelysin mRNA accumulation while having no effect on epidermal 
growth factor-induced or basal levels of mRNA for both enzymes. Western blots (collagenase) of conditioned media confirmed that PC 
blocked crystal-induced proteinase secretion as well. Moreover, PC (10-3 M) also blocked the crystal induction of c-fos and c-jun. Since 
FOS and JUN proteins form a transacting activator (AP-1) for expression of collagenase and stromelysin genes, PC may block the 
synthesis of both enzymes by inhibiting the transcription of c-fos and c-jun. 
Keywords: Phosphocitrate; Metalloproteinase; Calcium crystal; AP-1; Inhibition 
1. Introduction 
Calcium-containing crystal deposition diseases which 
include CPPD [ 1 ] and BCP (carbonate substituted hydroxy- 
apatite, octa-calciumphosphate nd tricalcium phosphate) 
[2] crystal deposition diseases, are a group of clinically 
heterogeneous arthritides which are a significant source of 
morbidity in the elderly. The etiology of these diseases are 
unknown. 
Clinical observations and serial radiographic surveys 
support the thesis that crystal deposition causes degenera- 
tion and that the degeneration accompanying crystal depo- 
sition differs from that of primary osteoarthritis. Firstly, 
sequential radiographs of patients with familial chondro- 
calcinosis due to CPPD deposition demonstrate cartilage 
calcification antedating radiographic signs of degeneration 
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[3]. Secondly, the degeneration associated with crystal 
deposits is often clinically distinct from degeneration of 
primary osteoarthritis. The distribution of joint involve- 
ment is an important distinguishing feature. Clinically, 
osteoarthritis in elbows, shoulders, wrists, and metacarpal 
phalangeal joints raises suspicion of calcium crystal depo- 
sition [1]. 
Calcium-containing crystals such as BCP and CPPD in 
concentrations found in human joint fluid, stimulate fibrob- 
lasts, synovial cells, and chondrocytes mitogenesis in vitro 
by a process similar to that of platelet-derived growth 
factor (PDGF) [4]. Moreover, BCP crystals and PDGF 
exert similar biologic effects on cultured cells, such as 
stimulation of PGE 2 production via the phospholipase 
A2/cyclo-oxygenase pathway [5], activation of phospho- 
lipase C and inositol phospholipid hydrolysis [6], and 
induction of collagenase and neutral protease stromelysin 
synthesis [7,8] and induction of proto-oncogenes (c-fos and 
c-myc) [9,10]. 
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Based on the clinical and synovial fluid findings and the 
in vitro data [11], a hypothesis has been formulated con- 
cerning the pathogenesis of calcium-containing crystal de- 
position diseases. Synovial lining cells phagocytose crys- 
tals in the joint fluid. In the process and/or as a result of 
endocytosis, ynovial cells respond with: (1) metallopro- 
teinase (MP) synthesis and release which in turn releases 
additional crystals and collagen from the surrounding tis- 
sue: (2) PGE 2 production: (3) DNA synthesis as a result of 
protein kinase C activation and crystal dissolution. MP and 
PGE 2 cause the 'degeneration' of the periarticular tissue. 
DNA synthesis leads to an increase in synovial cells that 
generate more proteases and PGE 2. Mechanical factors 
also contribute to joint destruction [12]. 
Our present understanding of the mechanisms of patho- 
logical calcification is limited, therefore no reliable method 
exists to prevent calcium crystal deposition. If crystals 
promote chondrolysis, then removal of crystals from the 
joint would be therapeutic. This can be accomplished in
gout where a systemic accumulation of urate can be tar- 
geted and eliminated with uricosuric or other hypouricemic 
therapy. Unfortunately, no systemic defect has been specif- 
ically recognized underlying most cases of calcium-con- 
taining crystal deposits. Directly solubilizing crystals by 
joint lavage in a patient with CPPD crystal deposition 
resulted in acute pseudogout attacks. 
Phosphocitrate (PC) is a naturally occurring compound 
which has been identified in mammalian mitochondria and 
in crab hepatopancreas, nd in minute quantities in human 
urine [13]. It has been speculated that PC may have an 
important role in preventing calcium phosphate precipita- 
tion in cells or cellular compartments maintaining high 
concentration of calcium and phosphate [14]. PC is a 
potent in vitro inhibitor of hydroxyapatite crystal forma- 
tion [15]. PC also prevents oft tissue calcification in vivo 
and does not produce any significant toxic side effect in rat 
or mice when given in doses up to 150 /zmol/kg/day 
[16,17]. 
In an earlier study, we showed that PC inhibited BCP 
crystal-induced c-fos mRNA accumulation transcription 
and mitogenesis n 3T3 cells in a dose-related fashion [18]. 
This inhibitory effect was specific since the same concen- 
trations of PC had no impact on basal, PDGF-induced or 
serum-induced mitogenesis and transcription of c-fos. A 
similar effect on protease secretion would offer prospects 
of a novel approach to prevention of crystal-induced de- 
generation. In the present study, we demonstrated that PC 
(10 -3 to 10 -4 M) inhibited both metalloproteinase MP 
(collagenase and stromelysin) and proto-oncogene (c-fos 
and c-jun) synthesis expected after stimulation of human 
fibroblasts with calcium-containing crystals. 
2. Material and methods 
Epidermal growth factor (EGF) was obtained from Col- 
laborative Research (Bedford, MA). Tritiated thymidine 
(50 Ci/mmol) and ECL Western blotting detection 
reagents were from Amersham (Arlington Heights, IL). 
Alpha-labeled [32P]dATP (3000 Ci/mmol) was from ICN 
(Irvine, CA). Fetal bovine serum, Hank's buffered saline 
solution and DMEM were supplied by GIBCO Laborato- 
ries (Grand Island, NY). Biotin-labeled goat anti-mouse 
IgG and peroxidase-labeled streptavidin were ordered from 
Kirkegaard and Perry Laboratories (Gaithersburg, MD). 
Molecular weight markers were obtained from Bio-Rad 
Laboratories (Richmond, CA). 
cDNA probes. The c-fos probe was a 1.3 kb PstI v-fos 
fragment from the p-fos-1/plasmid supplied by I Verma 
(Salk Instiute, San Diego, CA) [19]. The c-jun probe was a 
0.9 Kb BamHI/PstI insert from the RSV-cJ plasmid [20], 
supplied by Dr. Michael Karin (University of California, 
San Diego, CA). Northern blot analysis of stromelysin 
gene transcription was completed utilizing a 1.7 kb EcoRI 
insert from the pTR1 plasmid [21] kindly provided by Dr. 
Lynn Matrisian (Vanderbilt University, Nashville, TN). 
The collagenase probe, a 2.05 kb HindIII/SmaI insert 
from the pCllase 1 clone was obtained from the American 
Type Culture Collection [22]. The plasmid containing lyc- 
eraldehyde-3-phosphate dehydrogenase cDNA [23] came 
from the American Type Culture Collection. Probes were 
randomly primed with kits from Boehringer Mannheim 
(Indianapolis, IN). 
Antibody. The stromelysin anti-serum was raised against 
a synthetic peptide corresponding to amino acids 445-468 
of rat stromelysin [21]. Monoclonal antibody to collage- 
nase was a kind gift from Dr. Peter Mitchell (Pfizer Inc., 
Central Research Division, Groton, CT). 
Crystal and phosphocitrate (PC) preparation: BCP 
crystals were prepared by alkaline hydrolysis of brushite 
using a modification of the method of Bett et al. [24]. 
These crystals have a calcium/phosphate ratio of 1.59 and 
contained partially carbonate-substituted hydroxyapatite 
mixed with octacalcium phosphate by FTIR spectroscopy. 
Crystals were crushed in an agate mortar and sieved to 
yield 10-20 /zm aggregates which were sterilized and 
rendered pyrogen-free by heating at 20°C for 90 rain. 
CPPD crystals were made by methods published earlier 
[25] and sieved, sterilized and treated in a similar fashion 
as BCP crystals. Monosodium urate monohydrate (MSU) 
crystals, sized 10-30 /xm, were prepared from twice-re- 
crystallized uric acid and sodium hydroxide (Sigma, St. 
Louis, MO) as previously described [26]. X-ray diffraction 
showed only the interplanar spacings of MSU. 
PC was synthesized according to a procedure published 
earlier [27]. 
Cell culture: Human foreskin fibroblast (HF) cultures 
were established from explants and transferred. They were 
grown and maintained in DMEM supplemented with 10% 
fetal bovine serum (FBS) containing penicillin and strepto- 
mycin. All experiments were performed on confluent cell 
monolayers that had been rendered quiescent by removing 
the medium, washing with DMEM containing 0.5% FBS 
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and subsequently incubating in this medium for 24 h. All 
cultures used were third- or fourth-passage c lls. 
DNA synthesis assay: Cells were grown to confluence 
in culture dishes containing 24 wells, each 16-mm in 
diameter (Multiwell, Gibco) and rendered quiescent by 
incubating in 0.5% FBS for 24 h. Quiescent cells were 
then stimulated with 10% FBS, BCP crystals, CPPD crys- 
tals in the presence or absence of phosphocitrate in
DMEM-0.5% FBS. [3H]thymidine (1 /xCi/ml) was added 
to the wells 23 h after stimulation, and pulsed for 1 h. The 
cells were washed 3 times with phosphate-buffered saline 
(PBS), and macromolecules were precipitated with 5% 
trichloroacetic acid (TCA) solution. The precipitate was 
washed again with PBS and dissolved in 1 ml 0.1 N 
NaOH/0.1% sodium dodecyl sulfate (SDS). TCA-precipi- 
table radioactivity was determined in a liquid scintillation 
counter (Packard Instrument, Downer's Grove, IL). In 
previous experiments, the optimal concentrations to in- 
duced thymidine incorporation i  HF were BCP crystals 
(100 /xg/ml) and CPPD crystal (200/xg/ml) [28]. Unless 
otherwise specified, these were the concentrations of BCP 
and CPPD crystals used in all experiments. 
Northern blot analysis: Northern blot analysis of total 
cellular RNA was used to study the effect of PC on the 
expression of collagenase and stromelysin MRNA after 
stimulation by either BCP crystals or EGF. Control cul- 
tures were incubated in DMEM with or without PC. At 
times specified after stimulation, cells were scraped from 
100-mm plates, washed in physiological buffered saline 
and disrupted in guanidinium isothiocyanate. The RNA 
was then precipitated in 4 M lithium chloride as described 
by Cathala et al. [29]. RNA (5 /xg/lane) was elec- 
trophoresed on formaldehyde gels and transferred to nitro- 
cellulose filters as described previously [30]. The filters 
were hybridized with inserts purified from plasmid carry- 
ing sequences of the desired gene. The inserts were labeled 
to a specific activity greater than 108 cpm/#g using the 
random primer method [31]. 
Immunoprecipitation. One-ml samples of media, condi- 
tioned in the presence of 50 /zCi/ml [35S]methionine, 
were adjusted to 10 mM Tris (pH 7.4), 0.5% Triton X-100, 
0.1% SDS and 0.5% deoxycholate. 80 /.tl of a 50% 
suspension of protein A-sepharose CL-4B and 5 /xl of 
normal rabbit serum was added and the samples rocked at 
4°C for 2 h. The supernatant was removed after brief 
centrifugation, each sample split into 2 aliquots and 40 /xl 
of fresh protein-A sepharose added. 5/zl  of rat stromelysin 
antiserum was added to one of each duplicate samples and 
5 #1 of normal rabbit serum added to the other. The 
samples were rocked overnight at 4°C and the imrnuno- 
precipitates washed 3 times in immunoprecipitation buffer 
(10 mM Tris, pH 7.4, 0.5% Triton X-100, 0.1% SDS and 
0.5% deoxycholate) and once in phosphate-buffered saline. 
50 /.tl of 2 × SDS reducing sample buffer was added, the 
samples boiled, briefly centrifuged and the supernatants 
separated on a 10% polyacrylamide gel run. The gel was 
soaked in Fluoro-Hance (Research Products International 
Corp., Mount Prospect, IL), dried and exposed to film for 
3 days. 
Western blot analysis. Collagenase secretion was con- 
firmed by immunoblotting [32]. Briefly, samples of condi- 
tioned media from cultures timulated with BCP crystals in 
the presence or absence of PC, 12-0-tetradecanolyphorbol 
13-acetate (TPA), and unstimulated control were elec- 
trophoresed through 10% polyacrylamide g ls under educ- 
ing conditions and then transferred onto nitrocellulose 
membranes. After transfer, the membranes were incubated 
in 2.5% non-fat dry milk in Tris-buffered saline (TBS) (20 
mM Tris, 500 mM NaC1, pH 7.5) to eliminate non-specific 
binding of the antibodies to the membranes. The mem- 
branes were washed twice with Tween-20 solution (20 
mM Tris, 500 mM NaCI, 0.05% Tween-20) (TTBS). The 
membranes were then incubated with the antibody buffer 
(0.1% non-fat dry milk TTBS) containing 1 /zg/ml anti- 
collagenase antibody for 2 h at room temperature. The 
blots were then washed with TTBS and incubated with 
1 : 1,000 dilution of biotin-conjugated goat anti-mouse IgG. 
This was followed by washing with TTBS and incubation 
with a 1:1000 dilution of peroxidase-labeled streptavidin 
for 1 h. Membranes were washed twice with TTBS and 
once with TBS. Immunoreactive bands were visualized 
using Enhanced Chemiluminescent reagents (Amersham, 
Arlington Heights, IL) and Kodak Xomat film. 
cAMP assay: Plates were washed twice with cold 
physiological buffered saline and scraped into 1 ml of 
acidified (10 mM HC1) ethanol. The cells were broken 
with a dounce homogenizer and the suspension spun at 
4°C for 1.5 min in a microcentrifuge. The supernatant was 
removed, the precipitate resuspended in 1 ml of acidified 
ethanol and recentrifuged. Both supernatants were com- 
bined and evaporated to near dryness under a stream of 
nitrogen, cAMP was then assayed using a kit (TRK.432) 
from Amersham. 
Statistical analysis: All analysis of statistical signifi- 
cance was performed by Student's t-test. All experiments 
were run in quadruple, and repeated at least twice. 
3. Resu l ts  
Since the previous work on the inhibitory effect of PC 
was based on its effect on BCP crystal-induced mitogene- 
sis in Balb-3T3 cells [18], we examined the conditions 
under which PC may affect BCP and CPPD crystal-in- 
duced proliferation and metalloproteinase synthesis in HF. 
We confirmed that PC (10 -4 M) inhibited both BCP and 
CPPD crystal-induced mitogenesis in human fibroblasts, 
while it had little effect on basal (0.5% FBS) or serum-in- 
duced (10% FBS) mitogenesis (Fig. 1). 
Next, we examined the effect of various concentrations 
of PC on BCP crystal-induced collagenase and stromelysin 
mRNA accumulation in HF. PC (10 -3 and 10 -4 M) 
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Fig. 1. Inhibitory effect of PC on BCP and CPPD crystal-induced 
mitogenesis. Cells were grown to confluence in culture dishes containing 
24 wells, each 16 mm in diameter and rendered quiescent by incubating 
in 0.5% FBS for 24 h, [3H]Thymidine (1 /xCi/ml) was added to the 
wells 23 h after addition of BCP crystals, CPPD crystals or 10% FBS in 
the presence ([]) or absence (• )  of phospocitrate in DMEM-0.5% FBS, 
and pulsed for 1 h. The cells were then washed 3 times with PBS, and 
macromolecules were precipitated with 5% TCA solution. The precipitate 
was washed again with PBS and dissolved in 1 ml 0.1 N NaOH/0.1% 
SDS. TCA-precipitable radioactivity was determined in a liquid scintilla- 
tion counter. BCP (100 /zg/ml) and CPPD (200 /~g/ml) were used for 
this study. Control = 0.5% FBS. 
blocked BCP crystal-induced collagenase and stromelysin 
RNA expression significantly (Fig. 2). 
The specificity of inhibitory effect of PC on calcium- 
containing crystal-induced MP synthesis was tested. MSU 
crystals [33] and EGF [12,21] are powerful inducers of MP 
synthesis on cultured cells. While PC had a similar in- 
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Fig. 3. Effect of PC on accumulation of collagenase and stromelysin 
mRNA. Lane: (a) control, untreated culture; (b) CPPD crystals + PC (c) 
CPPD crystals; (d) MSU crystals; (e) MSU crystals+PC. PC (10 -3 M), 
CPPD and MSU crystal concentration (200 /zg/ml) were used. 
hibitory effect on CPPD crystal-induced MP expression, 
PC did not block the MSU crystal-induced collagenase and 
stromelysin mRNA accumulation (Fig. 3). Western blot 
analysis of the conditioned media from control and PC- 
treated cultures confirmed that PC blocked the crystal-in- 
duced collagenase synthesis while it had little effect on 
EGF-induced collagenase synthesis (Fig. 4). Immuno- 
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Fig. 2. Dose response of PC on accumulation of collagenase mRNA and 
stromelysin mRNA. Lane: (a and b) control, untreated culture; (c and d) 
BCP crystals; (e) BCP crystals+PC (10 -3 M); (f) BCP crystals+PC 
(10 -4 M); (g) BCP crystals+PC (10 -5 M); (h) BCP crystals+PC (10 -6 
M); (i) TPA (500 riM). BCP crystals (100/zg/ml)  were used in all cases. 
a b c d e f g h 
Fig. 4. Effect of PC on crystal-induced collagenase synthesis. Confluent 
HF were stimulated with BCP crystals or EGF in the presence or absence 
of PC (10 -3 M). Untreated and TPA-treated cultures were used as 
negative and positive control respectively. The culture medium were 
analysed by Western blotting using a specific monoclonal antibody to 
collagenase. Lane (a), molecular weight markers; (b) control, untreated 
culture; (c) BCP crystals; (d) BCP crystals + PC; (e) EGF (10 ng/ml);  (f) 
EFG+PC; (g) TPA (500 nM); (h) PC (10 -3 M) alone. 
H.S. Cheung et al. / Biochimica et Biophysica Acta 1315 (1996) 105-111 10~. 
-66  
18s  - 
Fos  
-45  
A B C D E 
Fig. 5. Immunoprecipitation of stromelysin from control and PC-treated 
cultures. Lane: (A) EGF; (B) EGF+PC; (C) BCP crystals; (D) BCP 
crystals+PC; (E) control, untreated culture. EGF (10 ng/ml),  BCP 
crystals (100 p~g/ml) and PC (10 3 M) were used. 
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Fig. 7. Effect of PC on c-fos transcription. Lane: (a) control, untreated 
culture; (b) control culture + PC; (c) BCP crysatls; (d) BCP crystals + PC: 
(e) EGF; (f) EGF+PC. BCP crystals (100 /zg/ml), PC (10 -4 M) and 
EGF (10 ng/ml)  were used. 
precipitation of stromelysin from the conditioned media 
from control and treated cultures also demonstrated the 
specific inhibitory effect of PC on crystal-induced 
stromelysin synthesis (Fig. 5). 
The suppression of collagenase mRNA accumulation, 
as a function of the time of PC addition, was measured to 
determine the time in the cell cycle at which the PC-medi- 
ated block occurred. PC could be added as late as 3 h after 
the cells were stimulated with BCP crystals, thereafter the 
inhibitory effect of PC decreases significantly (Fig. 6). 
The effects of PC on the induction of c-fos and c-jun 
expression by BCP crystals and EGF are summarized in 
Figs. 7 and 8. Stimulation of human fibroblasts with either 
BCP crystals or EGF resulted in maximal accumulation of 
c-fos mRNA 30 min after stimulation. In the presence of 
PC, the level of crystal-induced c-fos mRNA was greatly 
reduced (Fig. 7). PC also blocked the crystal-induced c-jun 
expression significantly at l and 3 h (Fig. 8). PC had little 
or no effect on the induction of c-fos and c-jun by EGF. 
Even in the presence of IBMX (phospodiesterase in-
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Fig. 8. Effect of PC on c-jun expression. The cells were rendered 
quiescent by serum deprivation for 24 h. The cells were then stimulated 
with either BCP crystal or EGF in the presence or absence of PC. The 
mRNA were harvested at 2 different time points 1 and 3 h after 
stimulation. For lane (a and b) mRNA were harvested at 1 h after 
stimulation. Lane (a) BCP crystals; (b) BCP crystals + PC For lane (c, d, 
e, f, and g) mRNA were harvested at 3 h post-stimulation. (c) control, 
untreated culture; (d) BCP crystals; (e) BCP crystals + PC; (f) EGF; (g) 
EGF + PC. 
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Fig. 6. Effect of delayed addition of PC on transcription of collagenase 
mRNA. The cells were rendered quiescent by serum deprivation for 24 h. 
At time 0, cells were stimulated with either BCP crystals (100/xg/ml)  or 
EGF (10 ng/ml).  Lane: (a) control, untreated cultures; (b and c) BCP 
crystals; (d and e) BCP crystals+PC added simultaneously. (f and g) 
BCP crystals + PC with PC added 1 h later; (h and i) BCP crystals + PC 
with PC added 3 h later; (j) EGF; (k) EGF+PC added simulataneously. 
(1) EGF+PC with PC added 1 h later. BCP (100/~g/ml),  PC (10 -4 M), 
and EGF (10 ng/ml)  were used. 
hibitor), PC (10 -3 M) did not stimulate any rise in cAMP 
in cells in the presence or absence of 100 txg/ml of BCP 
crystals (Table 1). In contrast, treatment with forskolin 
Table 1 
Effect of PC on intracellular cAMP levels 
Addition Time 
0 min 5 min 10 min 
IBMX 97+11 111+15 104+6 
PC + IBMX 121 +22 98+ 13 
PC + IBMX + BCP CRYSTALS 96± 18 100+2 
IBMX + Forskolin 2723 ± 388 2359_ 232 
Monolayers of HF were treated with IBMX (5x  10 -4 M), PC (10 -3 
M) + IBMX, PC + BCP crystals + IBMX, and IBMX + forskolin (2.5 × 
10 -5 M). After 5 min and 10 min, cells were harvested and cAMP 
extracted and assayed as described in Section 2. Data were expressed in 
pmol cAMP/106 cells. 
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(activator of adenyl cyclase) and IBMX induced a large 
sustained increase in cAMP. 
4. Discussion 
Our present data extend the earlier report [18] that PC 
inhibited BCP and CPPD crystal-induced mitogenesis in 
HF. This inhibitory effect was specific since the same 
concentrations of PC had no effect on basal, or serum-in- 
duced [3H]thymidine incorporation. We now show that PC 
(10 -3 to 10 -4 M) specifically inhibits the calcium-con- 
taining (BCP and CPPD) crystal induction of collagenase 
and stromelysin mRNA accumulation (Figs. 2 and 3) while 
having no effect on EGF-, MSU crystal-induced or basal 
levels of mRNA for both enzymes (Figs. 2 and 3). Western 
blot analysis and immunoprecipitation of conditioned me- 
dia confirmed that PC specifically blocked BCP crystal-in- 
duced collagenase and stromelysin secretion as well (Figs. 
4 and 5). 
The induction of c-fos and c-jun expressions are among 
the earliest responses to serum and growth factors in 
culture cells [34-36]. The fos protein, in combination with 
the protein products of c-jun, can serve as a trans-acting 
activator of the expression of other genes such as collage- 
nase and stromelysin [35,37,38]. McDonnell et al. reported 
that EGF stimulation of stromelysin required induction of 
c-fos, c-jun and activation of PKC [36]. Since BCP 
crystal-induced collagenase and stromelysin synthesis was 
preceded by a transient increase in the level of intracellular 
Ca 2÷, PKC activation, and c-fos, c-myc, c-jun induction 
[12], it is likely these same factors are required for crystal- 
induced MP synthesis. 
The present data showed that when PC (10 -3 M) was 
added with crystals, there was reduced mRNA for c-fos 
measured at 30 min and for c-jun measured at 1 and 3 h. 
These data support a mechanism in which PC blocks the 
synthesis of both enzymes by inhibiting the expressions of 
c-fos and c-jun. However, the present data do not rule out 
the possibilities that PC may have additional inhibitory 
effect on one or more other cellular esponses that regulate 
metalloproteinase synthesis. This suggests that it is possi- 
ble Fos and Jun are necessary but not sufficient for regula- 
tory collagenase synthesis. 
Elevated intracellular levels of cAMP have been shown 
to inhibit cytokine-induced synthesis of metalloproteinase 
[39-41] and mitogenesis [42,43] in a number of cell lines. 
Recently, we demonstrated a dose-dependent i hibition of 
serum and BCP crystal-induced mitogenesis and collage- 
nase mRNA accumulation by PGE l and its analog, miso- 
prostol [44] through a cAMP transduction pathway [45]. 
However, our present data would rule out such a mecha- 
nism for PC. Unlike the non-specific inhibitory effect of 
cAMP, PC specifically blocks crystal-induced mitogenesis 
and metalloproteinase synthesis while having no effect on 
EGF-induced or basal level of mRNA for both enzymes or 
serum-induced mitogenesis. 
Binding of PC on calcium-containing crystals is well 
documented [14-17]. Both SEM and light microscopy 
showed no changes in both BCP and CPPD crystals hape 
in the presence or absence of PC. Using 45Ca-labeled BCP 
crystals, we have shown that binding of PC to crystals 
cause no crystal dissolution, i.e., release of free 45Ca 
(Cheung et al., unpublished ata). Our working hypothesis 
of the mechanism of action of PC on BCP crystals is that 
binding of PC to crystal change the zeta potential of 
crystal surface, thus interfering with the crystal-membrane 
interaction that leads to cellular response. This would 
explaining why PC does not inhibit the monosodium urate 
crystals and peptide growth factor-induction f mitogene- 
sis and metalloproteinase synthesis. 
Recently, we reported that PC prevents the disease 
progression in murine progressive ankylosis (MPA), an 
animal model of crystal deposition disease [46]. MPA is a 
manifestation of an autosomal recessive mutation that pro- 
duces an inflammatory joint disorder associated with 
intra-articular BCP crystal deposition and culminates in 
fusion of the joints [47]. By treating 4-week-old MPA mice 
for 6 weeks with daily intraperitoneal injections of PC, 
disease progression in peripheral joints uninvolved at the 
start of treatment was significantly inhibited. Histologi- 
cally, there was marked inhibition of synovial prolifera- 
tion, chondroid metaplasia nd ankylosis in peripheral and 
spinal joints of PC-treated animals. PC inhibited disease 
progression i  MPA when given before disease was estab- 
lished. This may be due to inhibition of crystal-induced 
connective tissue cell proliferation and metalloproteinase 
synthesis as well as inhibition of calcification of articular 
tissues [46]. 
The association of calcium-containing crystals, such as 
BCP and CPPD, with osteoarthritis and various destructive 
arthropathies is well established. Degradation of the matrix 
molecules uch as collagen and proteoglycans, results, at 
least in part, from the metalloproteinase activities induced 
by the crystal stimulation of synovial cells. Synovial pro- 
liferation is also observed in joints containing BCP and 
CPPD crystals, presumably resulting from the mitogenic 
properties of these crystals. Currently available therapy is 
unsatisfactory [48]. Various non-steroidal anti-inflamma- 
tory agents have been used for both BCP and CPPD-re- 
lated arthropathies, but do not retard progressive joint 
degeneration. Both colchicine and intra-articular steroid 
injections have been used for the acute arthritis of pseudo- 
gout. These treatments control inflammation but also fail 
to retard chronic tissue destruction. 
PC is potentially valuable in the therapy of BCP and 
CPPD crystal deposition diseases for the following rea- 
sons. PC is a naturally occurring compound in mammalian 
tissue [13,14]. PC specifically inhibits the degenerative 
effect of crystals (e.g., metalloproteinase ynthesis and 
mitogenesis), and has been used successfully to prevent 
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disease progression i  an animal model of crystal deposi- 
tion disease [46]. Moreover, PC can prevent further crystal 
formation in the articular tissue since it is a powerful 
anti-mineralization effect both in vivo and in vitro [ 15-17]. 
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